1-(1-Benzothiophen-4-yl) Piperazinum Hydrochloridum CAS 913614-18-3 Puritas >98.0% (HPLC) Brexpiprazole Intermedia Factory

Description:

1-(1-Benzothiophen-4-yl) piperazinum hydrochloridum

CAS: 913614-18-3

Puritas: >99.0% (HPLC)

Aspectus: Alba ad Off-White pulveris

Medium Brexpiprazole (CAS: 913611-97-9)

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Brexpiprazole Intermedia
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl) piperazinum Hydrochloridum CAS 913614-18-3
7-(4-Chlorobutoxy) quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Nomen chemicum	1-(1-Benzothiophen-4-yl) piperazinum hydrochloridum
Synonyma	Brexpiprazole Medium 2;1-Benzo[b]thien-4-yl-Piperazinum hydrochloridum;1-Benzo[b]thien-4-ylpiperazinum Monohydrochloride
CAS Number	913614-18-3
CATTUS Number	RF-PI1034
Stock Status	In Stock, Productio Capacitas 100MT/Annus
Formulae hypotheticae	C12H15ClN2S
M. Pondus	254.7789
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Lepidium sativum	Retentione temporis specimen conforme est illi relationis vexillum
Puritas / Analysis Methodus	>99.0% (HPLC)
Damnum in Siccatio	<0.50%
Aquae (KF)	<0.50%
Residere in Ignition	<0.20%
Substantiae cognatae	(HPLC)
Omnis immunditia	<0.50%
Totalis immunditias	<1.00%
Infrared Imaginis	Conformat ut Structure
Proton NMR Spectrum	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Medium Brexpiprazole (CAS: 913611-97-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

1-(1-Benzothiophen-4-yl)piperazinum hydrochloridum (CAS: 913614-18-3) medium est Brexpiprazole (CAS: 913611-97-9).Brexpiprazole est genus atypicum antipsychoticum.Est dopamine D2 receptor partialis agonist.Cum nova actio modulatoris serotonin-dopamine, adhiberi potest ad tractationem schizophreniae et adiunctiva curatio pro tristitia.Praebere etiam potest efficaciam et tolerabilitatem in curationibus adiunctivis statutis inordinatio depressiva formajor (MDD).Medicamentum exhibet singularem profanum pharmacologicum, agonista serotonin 5-HT1A et dopamine receptorum 5-HT1A et tamquam plenus adversariorum receptorum 5-HT2A et noradrenalini α1B/2C, cum simili ligatura affinitatis subnanomolaris.Medicamentum, quod ab Otsuka et Lundbeck evolvit, anno 2015 ab FDA probatum est ad schizophreniae curationem et adiunctivam curationem pro tristitia.